









100/25/200mg - 30 Tab

13006

Code

0000 Cost price - JOD

0000

Public price - JOD

50/12.5/200mg - 30 Tab

13005 Code

Cost price - JOD 0000

Public price - JOD 0000

Product Name: Stalevo

Stalevo, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-O-methyltransferase-COMT inhibitor) is indicated for the treatment of Parkinson's disease.

Stalevo can be used:

- To substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products.
- To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose "wearing-off" and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias





Product Name: Orfarin

GRION

100 tablečiu

ORFARIN 5 mg

Constit. et color (E127

Orion Corporation

100 tablečiu


ORFARIN 3 mg

Active Ingredient : Warfarin

Drug Concentration: 3 mg - 5 mg

Orfarin is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and/or to prevent new clots from forming in your body. Preventing harmful blood clots helps to reduce the risk of a stroke or heart attack. Conditions that increase your risk of developing blood clots include a certain type of irregular heart rhythm (atrial fibrillation), heart valve replacement, recent heart attack, and certain surgeries (such as hip/knee replacement).

Warfarin is commonly called a "blood thinner," but the more correct term is "anticoagulant." It helps to keep blood flowing smoothly in your body by decreasing the amount of certain substances (clotting proteins) in your blood.







12.5mg

13001 Code

0000 Cost price - JOD

0000 Public price - JOD

Product Name: Simdax

Simdax (Levosimendan) is a calcium sensitizer — it increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan exerts its positive inotropic effect by increasing calcium sensitivity of myocytes by binding to cardiac troponin C in a calcium-dependent manner. It also has a vasodilatory effect by opening adenosine triphosphate (ATP)-sensitive potassium channels in vascular smooth muscle to cause smooth muscle relaxation.

The combined inotropic and vasodilatory actions result in an increased force of contraction, decreased preload and decreased afterload Moreover, by opening also the mitochondrial (ATP)-sensitive potassium channels in cardiomyocytes, the drug exerts a cardioprotective effect.